- Home
- BCDA vs MTEN Comparison
BCDA vs MTEN Comparison
Compare BCDA & MTEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCDA | MTEN |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 16.8M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | BCDA | MTEN |
|---|---|---|
| Price | $1.26 | $0.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 99.9K | ★ 989.5K |
| Earning Date | 11-12-2025 | 10-01-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,735,337.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.63 |
| 52 Week Low | $1.00 | $0.52 |
| 52 Week High | $3.20 | $26.03 |
Technical Indicators
Market Signals| Indicator | BCDA | MTEN |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 34.74 |
| Support Level | $1.16 | $0.52 |
| Resistance Level | $1.34 | $0.87 |
| Average True Range (ATR) | 0.09 | 0.15 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 32.79 | 70.40 |
Price Performance
Historical ComparisonAbout BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About MTEN Mingteng International Corporation Inc. Ordinary Shares
Mingteng International Corp Inc operates as an automotive mold developer and supplier in China. It provides an extensive product lineup including casting molds for turbocharger systems, braking systems, steering and differential systems, and other automotive system parts. Besides, it also produces molds for new energy electric vehicle motor drive systems, battery pack systems, and engineering hydraulic components, which are widely used in the automobile, construction machinery, and other manufacturing industries.